Get the Stockscreener App
2.925
0.86%
0.025
OncoCyte Corporation stock is traded at $2.925, with a volume of 15,966.
It is up +0.86% in the last 24 hours and up +1.21% over the past month.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
See More
Previous Close:
$2.90
Open:
$2.925
24h Volume:
15,966
Relative Volume:
0.84
Market Cap:
$48.96M
Revenue:
$1.02M
Net Income/Loss:
$-36.14M
P/E Ratio:
-0.2848
EPS:
-10.27
Net Cash Flow:
$-18.50M
1W Performance:
-5.65%
1M Performance:
+1.21%
6M Performance:
+9.96%
1Y Performance:
+15.16%
1-Day Range:
$2.85
$2.96
1-Week Range:
$2.85
$3.08
52-Week Range:
$2.08
$4.34
OncoCyte Corporation Stock (OCX) Company Profile
Name
OncoCyte Corporation
Sector
Industry
Phone
510-775-0515
Address
1010 Atlantic Avenue, Suite 102, Alameda, CA
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
OncoCyte Corporation Stock (OCX) Latest News
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - MarketBeat
StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX) - MarketBeat
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles - The Manila Times
Oncocyte Corp expands equity incentive plan - Investing.com India
Oncocyte Corp expands equity incentive plan By Investing.com - Investing.com Australia
OncoCyte shares maintain Buy rating from Needham By Investing.com - Investing.com Nigeria
OncoCyte shares maintain Buy rating from Needham - Investing.com
OncoCyte Corp (OCX) Q2 2024 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - Yahoo Finance
Oncocyte reports breakthrough in breast cancer diagnostics - Investing.com
Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial - The Manila Times
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial - StockTitan
Broadwood Partners L.P. buys Oncocyte shares for $3.88 million By Investing.com - Investing.com Australia
Oncocyte CFO acquires $99,999 worth of company shares By Investing.com - Investing.com South Africa
Oncocyte CFO acquires $99,999 worth of company shares - Investing.com
Broadwood Partners L.P. buys Oncocyte shares for $3.88 million - Investing.com
OncoCyte Secures Funding Through Private Share Sale - Yahoo Finance
OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc. - Marketscreener.com
LENSAR reports inducement grants - Medical Buyer
Oncocyte Corporation enters into securities purchase agreement - Medical Buyer
Oncocyte Signs Leading Transplant Centers in US and Germany - The Manila Times
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules - ForexTV.com
Sandfire Resources America Inc. Announces Incentive Plan Grants - The Manila Times
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Breast Biopsy Devices Market 2024 – Industry Scenario, Strategies, Growth Factors and Forecast 2032 | OncoCyte Corporation, Benetec - 대구포스트
Breast Cancer Predictive Genetic Testing Market 2024 Key Stakeholders, CAGR, Growth Factors and Forecast 2032 | OncoCyte Corporation, Myriad Genetics - 대구포스트
OncoCyte Corporation announced that it has received $10.203435 million in funding from Bio-Rad Laboratories, Inc. - Marketscreener.com
Raymond James Equities Analysts Increase Earnings Estimates for OceanaGold Co. (TSE:OGC) - MarketBeat
Orion (NYSE:OEC) Raised to “Buy” at StockNews.com - Defense World
Recent Insider Activity Suggests Potential Gains for Outset Medical Inc (OM) - Knox Daily
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Oscar Health Inc [OSCR] Investment Guide: What You Need to Know - Knox Daily
16,619 Shares in Owens Corning (NYSE:OC) Bought by Point72 DIFC Ltd - Defense World
Great Point Partners LLC Invests $15.73 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Market Highlights: Oscar Health Inc (OSCR) Ends on a Low Note at 22.33 - The Dwinnex
OM Stock on the Rise: A Promising Investment - The InvestChronicle
Was Outset Medical Inc (OM)’s session last reading good? - US Post News
Ondine Biomedical secures CAD5 million financing - Marketscreener.com
30,143 Shares in Oshkosh Co. (NYSE:OSK) Acquired by Magnetar Financial LLC - Defense World
Promising Progress in Oncology as Cancer Deaths Decline and Research Grows - Baystreet.ca
Views of Wall Street’s Leading Experts on Onconetix Inc - SETE News
Oscar Health, Inc. (NYSE:OSCR) Shares Acquired by Summit Trail Advisors LLC - Defense World
Ratio Review: Analyzing Ocugen Inc (OCGN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
First Light Asset Management LLC Sells 236,632 Shares of Oscar Health, Inc. (NYSE:OSCR) - MarketBeat
Financial Metrics Unveiled: Outset Medical Inc (OM)’s Key Ratios in the Spotlight - The Dwinnex
Onto Innovation Inc. (NYSE:ONTO) Shares Sold by Epoch Investment Partners Inc. - Defense World
Outset Medical, Inc. (NASDAQ:OM) Might Not Be As Mispriced As It Looks After Plunging 27% - Simply Wall St
ONWARD Medical lists on Euronext Paris - Euronext
American Century Companies Inc. Grows Stake in Osisko Gold Royalties Ltd (NYSE:OR) - MarketBeat
Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World
O-I Glass Inc (OI) Becoming More Attractive for Investors - Knox Daily
Owens Corning exec sells over $538k in company stock By Investing.com - Investing.com UK
OncoCyte Corporation Stock (OCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):